Haemonetics price target raised to $88 from $85 at BTIG

BTIG raised the firm’s price target on Haemonetics (HAE) to $88 from $85 and keeps a Buy rating on the shares after the company beat expectations across all business segments, reset Hospital guidance to “an achievable level,” and raised the total sales outlook for FY26. Arguing that this quarter’s execution was a positive lift for credibility on both operations and messaging, the firm thinks shares can continue “a gradual recovery from here,” the analyst tells investors.